Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.45 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.45 |
| ▸ | ITGAL | P20701 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182303 | 1.00 | ECE1 (0.53) | ECE1MEN1KMT2ACA2CA4 | |
| SCHEMBL4182306 | 1.00 | ECE1 (0.53) | ECE1MEN1KMT2ACA2CA4 | |
| SCHEMBL7358176 | 0.86 | ECE1 (0.51) | ECE1MEN1KMT2ACA2CA4 | |
| SCHEMBL15811060 | 0.86 | ECE1 (0.51) | ECE1MEN1KMT2ACA2CA4 | |
| SCHEMBL7358174 | 0.86 | ECE1 (0.51) | ECE1MEN1KMT2ACA2CA4 | |
| SCHEMBL15605900 | 0.85 | CA2 (0.60) | CA2CA4CYP2C9MMEPIN1 | |
| SCHEMBL4177568 | 0.85 | CA2 (0.60) | CA2CA4CYP2C9MMEPIN1 | |
| SCHEMBL4177566 | 0.85 | CA2 (0.60) | CA2CA4CYP2C9MMEPIN1 | |
| SCHEMBL25169531 | 0.85 | ECE1 (0.50) | ECE1MEN1KMT2ACA2ITGB2 | |
| SCHEMBL21724473 | 0.85 | ECE1 (0.50) | ECE1MEN1KMT2ACA2ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | ECE1 1624/4885MEN1 855/4885KMT2A 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.